Skip to main content
NIH funding notice RFA-DK-21-006

Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional)

Closed on October 20, 2021.

Posted
April 6, 2021
Close date
October 20, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
3
3 new
Median first-year cost
$798,092
$2,245,478 in all
Institutions
3
3 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. GEORGIA INSTITUTE OF TECHNOLOGY1
  2. METHODIST HOSPITAL RESEARCH INSTITUTE1
  3. WEILL MEDICAL COLL OF CORNELL UNIV1

Most frequent study sections

  1. Special Emphasis Panel (ZDK1 GRB-G (M3))3
3 awards under RFA-DK-21-006 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2022Hydrogels for human beta cell survival, function and evasion of immune rejection1R01DK133702-01Garcia, Andres JMarkmann, James FrancisShirwan, HavalGEORGIA INSTITUTE OF TECHNOLOGY, GAFirst-year cost $822,338Study section ZDK1
FY2022Vascularized NICHE with local immunosuppression for cell replacement for Type 1 diabetes1R01DK133610-01Grattoni, AlessandroKenyon, Norma S.METHODIST HOSPITAL RESEARCH INSTITUTE, TXFirst-year cost $798,092Study section ZDK1
FY2022Engineering islet-like organoids from gastric stem cells for T1D cell replacement therapy1R01DK133701-01Zhou, Qiao JoeWEILL MEDICAL COLL OF CORNELL UNIV, NYFirst-year cost $625,048Study section ZDK1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-15-0.3.4. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-DK-21-006: Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional) | ScienceDex | ConductScience